Abstract: The claimed invention is directed to the use of a composition for use as an antimicrobial comprising an antimicrobial agent. In certain embodiments, the composition is used for treating or ameliorating inflammation in a subject and comprises an anti-inflammatory agent. The anti-inflammatory agent may include an NSAID, such as ibuprofen or diclofenac. The composition may further include solvents, anti-bacterial agents, anti-fungal agents, anti-parasitic agents, anti-viral agents, and buffers. The composition may include particles that have been processed via jet milling to reduce a diameter of the particles and to improve a flowability of the particles.

Abstract: The claimed invention is directed to the use of a composition for use as an antimicrobial comprising an antimicrobial agent. In certain embodiments, the composition is used for treating or ameliorating inflammation in a subject and comprises an anti-inflammatory agent. The anti-inflammatory agent may include an NSAID, such as ibuprofen or diclofenac. The composition may further include solvents, anti-bacterial agents, anti-fungal agents, anti-parasitic agents, anti-viral agents, and buffers. The composition may include particles that have been processed via jet milling to reduce a diameter of the particles and to improve a flowability of the particles.

Abstract: The claimed invention is directed to the use of a composition for use as an antimicrobial comprising an antimicrobial agent. In certain embodiments, the composition is used for treating or ameliorating inflammation in a subject and comprises an anti-inflammatory agent. The anti-inflammatory agent may include an NSAID, such as ibuprofen or diclofenac. The composition may further include solvents, anti-bacterial agents, anti-fungal agents, anti-parasitic agents, anti-viral agents, and buffers. The composition may include particles that have been processed via jet milling to reduce a diameter of the particles and to improve a flowability of the particles.

Abstract: Active multifunctional nanoparticles provide significant enhancement of the efficacy of model therapeutic and gene agents due to increased diffusion and penetration through mucus and biological barriers under the influence of a magnetic field.

Abstract: A dry powder delivery device may be configured to provide micronized dry powder particles to airways of a user. The device may include a cylindrical container delimiting a chamber containing at least one magnetically-responsive object, a motor external to said chamber, a magnet external to the chamber and rotatably coupled with the motor, and an outflow member configured to direct airflow to a user. The magnetically-responsive object may be coated with micronized dry powder particles, and the motor may be operable to rotate the magnet about an axis. Rotation of the magnet creates a magnetic field that causes the magnetically-responsive object to move in response to the magnetic field and collide with a side wall of the container to deaggregate the dry powder particles and aerosolize the dry powder in the chamber.

Abstract: Swellable particles for delivering a working agent to the pulmonary system comprise a plurality of biodegradable particles each formed from a polymer network, each of the plurality of biodegradable particles having a mass mean aerodynamic diameter not exceeding 5 ?m, the particles being swellable by hydration to a size that is greater than 6 ?m volume mean diameter, and a working agent entrapped in the polymer network of each of the plurality of biodegradable particles.

Abstract: Swellable particles for delivery of a drug or other working agent to the pulmonary system are provided. The swellable particles include a dehydrated (dry) aerodynamic particle diameter of 5 ?m or less to enable delivery to the respiratory tract, such as for example to the tracheo-bronchial airways of the upper respiratory tract and/or to the alveolic regions of the deep lung, and a hydrated particle diameter that is greater than 6 ?m volume mean diameter to retard or prevent their phagocytosis by the macrophages present in airways of the respiratory tract.

Abstract: A dry powder delivery device may be configured to provide micronized dry powder particles to airways of a user. The device may include a cylindrical container delimiting a chamber containing at least one magnetically-responsive object, a motor external to said chamber, a magnet external to the chamber and rotatably coupled with the motor, and an outflow member configured to direct airflow to a user. The magnetically-responsive object may be coated with micronized dry powder particles, and the motor may be operable to rotate the magnet about an axis. Rotation of the magnet creates a magnetic field that causes the magnetically-responsive object to move in response to the magnetic field and collide with a side wall of the container to deaggregate the dry powder particles and aerosolize the dry powder in the chamber.

Abstract: Swellable particles for delivery of a drug or other working agent to the pulmonary system are provided. The swellable particles include a dehydrated (dry) aerodynamic particle diameter of 5 ?m or less to enable delivery to the respiratory tract, such as for example to the tracheo-bronchial airways of the upper respiratory tract and/or to the alveolic regions of the deep lung, and a hydrated particle diameter that is greater than 6 ?m volume mean diameter to retard or prevent their phagocytosis by the macrophages present in airways of the respiratory tract.

Abstract: Swellable particles for delivery of a drug or other working agent to the pulmonary system are provided. The swellable particles include a dehydrated (dry) aerodynamic particle diameter of 5 ?m or less to enable delivery to the respiratory tract, such as for example to the tracheo-bronchial airways of the upper respiratory tract and/or to the alveolic regions of the deep lung, and a hydrated particle diameter that is greater than 6 ?m volume mean diameter to retard or prevent their phagocytosis by the macrophages present in airways of the respiratory tract.

Abstract: Active multifunctional nanoparticles provide significant enhancement of the efficacy of model therapeutic and gene agents due to increased diffusion and penetration through mucus and biological barriers under the influence of a magnetic field.